Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Apr 1;42(4):298-312.
doi: 10.1097/EJA.0000000000002126. Epub 2025 Feb 4.

Remimazolam for procedural sedation: A systematic review with meta-analyses and trial sequential analyses

Lasse Pingel  1 , Mathias Maagaard, Casper D Tvarnø, Sandra Sorenson, Shaheer Bukhari, Lars Peter Kloster Andersen, Jakob Hessel Andersen, Ole Mathiesen
Affiliations
Meta-Analysis

Remimazolam for procedural sedation: A systematic review with meta-analyses and trial sequential analyses

Lasse Pingel et al. Eur J Anaesthesiol. .

Abstract

Background: Midazolam and propofol are frequently used for procedural sedation. Remimazolam may provide a more controllable sedation with fewer adverse effects.

Objective: To assess the sedation success rate and respiratory and cardiovascular complications of remimazolam versus placebo and other sedatives in adults undergoing procedural sedation.

Design: A systematic review of randomised controlled trials (RCTs) with meta-analyses, trial sequential analyses (TSA), and GRADE evaluations of the certainty of evidence.

Data sources: We searched Medline, Embase, CENTRAL, BIOSIS, CINAHL, and Web of Science Core Collection from their inception to 22 June 2024.

Eligibility criteria: RCTs allocating participants undergoing procedural sedation to remimazolam versus placebo or any active comparator.

Results: We included 63 trials randomising 13 953 participants. All included trial results were judged to be at high risk of bias. The sedation success rate was similar with remimazolam versus active comparators, relative risk (RR) 1.04, [97.5% confidence interval (CI), 0.96 to 1.14; TSA-adjusted CI, 0.95 to 1.18], P = 0.26, GRADE: very low. Subgroup analyses indicated that remimazolam versus midazolam increased sedation success rate, while the risks were similar with remimazolam versus comparators. Remimazolam versus active comparators decreased the risk of respiratory complications, RR 0.47, (97.5% CI, 0.36 to 0.61; TSA-adjusted CI, 0.35 to 0.61), P < 0.01; and cardiovascular complications, RR 0.46, (97.5% CI, 0.37 to 0.56; TSA-adjusted CI, 0.38 to 0.57), P < 0.01. Subgroup analyses indicated that remimazolam versus propofol reduced respiratory and cardiovascular complications, while the risks were similar versus midazolam.

Conclusion: Remimazolam seems to provide a similar sedation success rate as other active comparators (propofol, ciprofol, midazolam, dexmedetomidine, etomidate), although subgroup analyses indicated that remimazolam increased sedation success rate compared to midazolam. Remimazolam compared to propofol may decrease the risk of respiratory and cardiovascular complications. The certainty of the evidence was very low to low, and firm conclusions could not be drawn.

PubMed Disclaimer

References

    1. Hara T, Ozawa A, Shibutani K, et al. Working Group for the Preparation of Practical Guidelines for Safe Sedation SCotJSoA. Practical guide for safe sedation. J Anesth 2023; 37:340–356.
    1. Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018: a report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. Anesthesiology 2018; 128:437–479.
    1. Hari Keerthy P, Balakrishna R, Srungeri KM, et al. Comparitive evaluation of propofol and midazolam as xonscious sedatives in minor oral surgery. J Maxillofac Oral Surg 2015; 14:773–783.
    1. Keam SJ. Remimazolam: first approval. Drugs 2020; 80:625–633.
    1. Pastis NJ, Yarmus LB, Schippers F, et al. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest 2019; 155:137–146.

MeSH terms